Hennion & Walsh Asset Management, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $258,155 - $271,228	-1,781 Reduced 4.0%	42,694 $6.45 Million
Q2 2022 Jul 19, 2022	SELL	$83.14 - $145.99 $3.34 Million - $5.86 Million	-40,134 Reduced 47.43%	44,475 $6.48 Million
Q1 2022 Apr 26, 2022	SELL	$110.08 - $142.92 $301,399 - $391,314	-2,738 Reduced 3.13%	84,609 $10 Million
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $2.69 Million - $4 Million	-26,939 Reduced 23.57%	87,347 $12 Million
Q3 2021 Nov 12, 2021	BUY	$98.85 - $138.91 $91,337 - $128,352	924 Added 0.82%	114,286 $15.9 Million
Q2 2021 Aug 13, 2021	BUY	$65.78 - $105.02 $1.04 Million - $1.67 Million	15,864 Added 16.27%	113,362 $11 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $6.25 Million - $8.95 Million	97,498 New	97,498 $6.66 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.